These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 36621846)

  • 1. Dihydropyrimidinase-like 2 can serve as a novel therapeutic target and prognostic biomarker in acute myeloid leukemia.
    Li F; Ling Q; Lian J; Chen Y; Hu C; Yang M; Zhang X; Li C; Mao S; Ye W; Li X; Lin X; Wei W; Huang X; Pan J; Qian Y; Wang J; Lu Y; Jin J
    Cancer Med; 2023 Apr; 12(7):8319-8330. PubMed ID: 36621846
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Spermatogenesis associated serine rich 2 like plays a prognostic factor and therapeutic target in acute myeloid leukemia by regulating the JAK2/STAT3/STAT5 axis.
    Li F; Ye W; Yao Y; Wei W; Lin X; Zhuang H; Li C; Li X; Ling Q; Hu C; Huang X; Qian Y; Mao S; Huang J; Lu Y; Jin J
    J Transl Med; 2023 Feb; 21(1):115. PubMed ID: 36774517
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Homoharringtonine is synergistically lethal with BCL-2 inhibitor APG-2575 in acute myeloid leukemia.
    Wei W; Huang S; Ling Q; Mao S; Qian Y; Ye W; Li F; Pan J; Lin X; Huang J; Huang X; Zhai Y; Sun J; Jin J
    J Transl Med; 2022 Jul; 20(1):299. PubMed ID: 35794605
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Homoharringtonine affects the JAK2-STAT5 signal pathway through alteration of protein tyrosine kinase phosphorylation in acute myeloid leukemia cells.
    Tong H; Ren Y; Zhang F; Jin J
    Eur J Haematol; 2008 Oct; 81(4):259-66. PubMed ID: 18616510
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regulatory role of RBM39 in acute myeloid leukemia: Mediation through the PI3K/AKT pathway.
    Zhang X; Yang L; Liu X; Nie Z; Liu M; Wang T; Lu Y; Pan Y; Zhan Y; Wang Z; Luo J
    Biochim Biophys Acta Mol Cell Res; 2024 Jan; 1871(1):119607. PubMed ID: 37852323
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synergistic killing effects of homoharringtonine and arsenic trioxide on acute myeloid leukemia stem cells and the underlying mechanisms.
    Tan M; Zhang Q; Yuan X; Chen Y; Wu Y
    J Exp Clin Cancer Res; 2019 Jul; 38(1):308. PubMed ID: 31307525
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Downregulation of SMIM3 inhibits growth of leukemia via PI3K-AKT signaling pathway and correlates with prognosis of adult acute myeloid leukemia with normal karyotype.
    Liu Y; Chen Y; Liu Y; Li M; Zhang Y; Shi L; Yang L; Li T; Li Y; Jiang Z; Liu Y; Wang C; Wang S
    J Transl Med; 2022 Dec; 20(1):612. PubMed ID: 36550462
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MAP4K1 functions as a tumor promotor and drug mediator for AML via modulation of DNA damage/repair system and MAPK pathway.
    Ling Q; Li F; Zhang X; Mao S; Lin X; Pan J; Ye W; Wei W; Qian Y; Hu C; Huang X; Wang J; Wang H; Huang J; Wang Y; Jin J
    EBioMedicine; 2021 Jul; 69():103441. PubMed ID: 34166980
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Homoharringtonine targets Smad3 and TGF-β pathway to inhibit the proliferation of acute myeloid leukemia cells.
    Chen J; Mu Q; Li X; Yin X; Yu M; Jin J; Li C; Zhou Y; Zhou J; Suo S; Lu D; Jin J
    Oncotarget; 2017 Jun; 8(25):40318-40326. PubMed ID: 28454099
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Homoharringtonine synergizes with quizartinib in FLT3-ITD acute myeloid leukemia by targeting FLT3-AKT-c-Myc pathway.
    Wang F; Huang J; Guo T; Zheng Y; Zhang L; Zhang D; Wang F; Naren D; Cui Y; Liu X; Qu Y; Luo H; Yang Y; Wei H; Guo Y
    Biochem Pharmacol; 2021 Jun; 188():114538. PubMed ID: 33831397
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Homoharringtonine synergy with oridonin in treatment of t(8; 21) acute myeloid leukemia.
    Zhang W; Lu Y; Zhen T; Chen X; Zhang M; Liu P; Weng X; Chen B; Wang Y
    Front Med; 2019 Jun; 13(3):388-397. PubMed ID: 30206768
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Homoharringtonine suppresses LoVo cell growth by inhibiting EphB4 and the PI3K/AKT and MAPK/EKR1/2 signaling pathways.
    Shi X; Zhu M; Gong Z; Yang T; Yu R; Wang J; Zhang Y
    Food Chem Toxicol; 2020 Feb; 136():110960. PubMed ID: 31726078
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Abivertinib, a novel BTK inhibitor: Anti-Leukemia effects and synergistic efficacy with homoharringtonine in acute myeloid leukemia.
    Huang S; Pan J; Jin J; Li C; Li X; Huang J; Huang X; Yan X; Li F; Yu M; Hu C; Jin J; Xu Y; Ling Q; Ye W; Wang Y; Jin J
    Cancer Lett; 2019 Oct; 461():132-143. PubMed ID: 31310800
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Homoharringtonine deregulates
    Chen XJ; Zhang WN; Chen B; Xi WD; Lu Y; Huang JY; Wang YY; Long J; Wu SF; Zhang YX; Wang S; Li SX; Yin T; Lu M; Xi XD; Li JM; Wang KK; Chen Z; Chen SJ
    Proc Natl Acad Sci U S A; 2019 Feb; 116(6):2220-2225. PubMed ID: 30659143
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synergistic efficacy of homoharringtonine and venetoclax on acute myeloid leukemia cells and the underlying mechanisms.
    Yuan F; Li D; Li G; Cheng C; Wei X
    Ann Transl Med; 2022 Apr; 10(8):490. PubMed ID: 35571387
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High NCALD expression predicts poor prognosis of cytogenetic normal acute myeloid leukemia.
    Song Y; Zhang W; He X; Liu X; Yang P; Wang J; Hu K; Liu W; Zhang X; Jing H; Yuan X
    J Transl Med; 2019 May; 17(1):166. PubMed ID: 31109331
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The efficacy and safety of a homoharringtonine-based protocol for children with acute myeloid leukemia: A retrospective study in China.
    Tang Y; Luo C; Shen S; Xue H; Pan C; Hu W; Chen X; Cai J; Chen J; Tang J
    Pediatr Hematol Oncol; 2021 Mar; 38(2):97-107. PubMed ID: 33016804
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of Hedgehog Pathway Mediator GLI Represents a Negative Prognostic Marker in Human Acute Myeloid Leukemia and Its Inhibition Exerts Antileukemic Effects.
    Wellbrock J; Latuske E; Köhler J; Wagner K; Stamm H; Vettorazzi E; Vohwinkel G; Klokow M; Uibeleisen R; Ehm P; Riecken K; Loges S; Thol F; Schubert C; Amling M; Jücker M; Bokemeyer C; Heuser M; Krauter J; Fiedler W
    Clin Cancer Res; 2015 May; 21(10):2388-98. PubMed ID: 25745035
    [TBL] [Abstract][Full Text] [Related]  

  • 19. miR-338-3p Plays a Significant Role in Casticin-Induced Suppression of Acute Myeloid Leukemia via Targeting PI3K/Akt Pathway.
    Yu K; Wang J; Hou J; Zhang L; Liang H
    Biomed Res Int; 2022; 2022():9214130. PubMed ID: 35765408
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Homoharringtonine potentiates the antileukemic activity of arsenic trioxide against acute myeloid leukemia cells.
    Chen P; Zhan W; Wang B; You P; Jin Q; Hou D; Wang X; You R; Zou H; Chen Y; Huang H
    Exp Cell Res; 2019 Mar; 376(2):114-123. PubMed ID: 30763586
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.